Ashish Bhargava1, Ulka N Vaishampayan. 1. Department of Medicine, Division of Hematology/Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
Abstract
BACKGROUND: In recent years, JM-216/satraplatin (GPC Biotech, Inc.) has emerged as a novel oral platinum analogue with a better toxicity profile than cisplatin. Since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it appears to demonstrate efficacy in cisplatin-resistant cell lines. The preclinical and clinical evaluation of satraplatin stimulated this review of the pharmacology and clinical trial data of this agent. METHODS: A literature review was conducted in the MEDLINE database from 1985 to present using the keywords 'satraplatin' or 'JM-216'. The abstracts regarding satraplatin reported at the 2007 - 2009 American Society of Clinical Oncology meetings were also reviewed. RESULTS/ CONCLUSION: Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA-approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate-resistant prostate cancer (CRPC), revealing an improvement in progression-free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel-refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.
BACKGROUND: In recent years, JM-216/satraplatin (GPC Biotech, Inc.) has emerged as a novel oral platinum analogue with a better toxicity profile than cisplatin. Since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it appears to demonstrate efficacy in cisplatin-resistant cell lines. The preclinical and clinical evaluation of satraplatin stimulated this review of the pharmacology and clinical trial data of this agent. METHODS: A literature review was conducted in the MEDLINE database from 1985 to present using the keywords 'satraplatin' or 'JM-216'. The abstracts regarding satraplatin reported at the 2007 - 2009 American Society of Clinical Oncology meetings were also reviewed. RESULTS/ CONCLUSION:Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA-approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate-resistant prostate cancer (CRPC), revealing an improvement in progression-free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel-refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.
Authors: S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Marc Trudeau; Gavin Stuart; Hal Hirte; Pierre Drouin; Marie Plante; Paul Bessette; Helene Dulude; David Lebwohl; Bryn Fisher; Lesley Seymour Journal: Gynecol Oncol Date: 2002-02 Impact factor: 5.482
Authors: Tahir Latif; Laura Wood; Cindy Connell; David C Smith; David Vaughn; David Lebwohl; David Peereboom Journal: Invest New Drugs Date: 2005-01 Impact factor: 3.850
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: L R Kelland; G Abel; M J McKeage; M Jones; P M Goddard; M Valenti; B A Murrer; K R Harrap Journal: Cancer Res Date: 1993-06-01 Impact factor: 12.701
Authors: Ulka N Vaishampayan; Joseph Fontana; Lance K Heilbrun; Daryn Smith; Elisabeth Heath; Brenda Dickow; William D Figg Journal: Urol Oncol Date: 2013-02-21 Impact factor: 3.498
Authors: Ulka Vaishampayan; Daniel Shevrin; Mark Stein; Lance Heilbrun; Susan Land; Karri Stark; Jing Li; Brenda Dickow; Elisabeth Heath; Daryn Smith; Joseph Fontana Journal: Urology Date: 2015-09-12 Impact factor: 2.649